Dipeptidyl Peptidase IV as a Muscle Myokine
- PMID: 32194435
- PMCID: PMC7063094
- DOI: 10.3389/fphys.2020.00148
Dipeptidyl Peptidase IV as a Muscle Myokine
Abstract
Dipeptidyl peptidase IV (DPP-IV) is a unique serine protease that exists in a membrane bound state and in a soluble state in most tissues in the body. DPP-IV has multiple targets including cytokines, neuropeptides, and incretin hormones, and plays an important role in health and disease. Recent work suggests that skeletal muscle releases DPP-IV as a myokine and participates in control of muscle blood flow. However, few of the functions of DPP-IV as a myokine have been investigated to date and there is a poor understanding about what causes DPP-IV to be released from muscle.
Keywords: exercise; metalloproteases; muscle; peptidase; secretome; whey protein.
Copyright © 2020 Kluess.
Figures
Similar articles
-
The serine protease, dipeptidyl peptidase IV as a myokine: dietary protein and exercise mimetics as a stimulus for transcription and release.Physiol Rep. 2016 Jun;4(12):e12827. doi: 10.14814/phy2.12827. Physiol Rep. 2016. PMID: 27335432 Free PMC article.
-
Endogenous dipeptidyl peptidase IV modulates skeletal muscle arteriolar diameter in rats.Physiol Rep. 2018 Jan;6(2):e13564. doi: 10.14814/phy2.13564. Physiol Rep. 2018. PMID: 29380955 Free PMC article.
-
The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.Curr Med Chem. 1999 Apr;6(4):311-27. Curr Med Chem. 1999. PMID: 10101215 Review.
-
Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?J Med Chem. 2014 Mar 27;57(6):2197-212. doi: 10.1021/jm400658e. Epub 2013 Oct 24. J Med Chem. 2014. PMID: 24099035 Review.
-
Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.J Asian Nat Prod Res. 2017 Oct;19(10):1036-1045. doi: 10.1080/10286020.2017.1307183. Epub 2017 Mar 29. J Asian Nat Prod Res. 2017. PMID: 28351157 Review.
Cited by
-
Myokines: Novel therapeutic targets for diabetic nephropathy.Front Endocrinol (Lausanne). 2022 Oct 25;13:1014581. doi: 10.3389/fendo.2022.1014581. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36387916 Free PMC article. Review.
-
A Comprehensive Review and Perspective on Natural Sources as Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes.Pharmaceuticals (Basel). 2021 Jun 20;14(6):591. doi: 10.3390/ph14060591. Pharmaceuticals (Basel). 2021. PMID: 34203048 Free PMC article. Review.
References
-
- Akarte A. S., Srinivasan B. P., Gandhi S., Sole S. (2012). Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats. Eur. J. Pharm. Sci. 47 456–463. 10.1016/j.ejps.2012.07.003 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
